Ticker Launch
Sign inTry it free

Reverse merger · Completed · GYRE

Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group)

Reverse merger with Catalyst Biosciences, Inc. (CBIO)

Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group) merged into Catalyst Biosciences, Inc. (CBIO), a Nasdaq-listed clinical-stage biotech that sold legacy assets and distributed cash, in a reverse merger that takes the private company public. The deal was announced on Dec 27, 2022 and closed on Oct 30, 2023. The combined company trades as Gyre Therapeutics, Inc. (GYRE) on Nasdaq.

Gyre Therapeutics is a biopharmaceutical company focused on organ fibrosis and inflammatory diseases. Its operations center on Beijing Continent Pharmaceuticals, a China-based commercial company that markets pirfenidone for idiopathic pulmonary fibrosis and runs a fibrosis clinical pipeline.

Status
Completed
Private company
Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group)
Public company
Catalyst Biosciences, Inc. (CBIO)
Public company business before
Nasdaq-listed clinical-stage biotech that sold legacy assets and distributed cash
Announced
Dec 27, 2022
Closed
Oct 30, 2023
Combined company
Gyre Therapeutics, Inc. (GYRE)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers